IP Library Granted Patent US 7,943,141
Granted Patent B2
US 7,943,141 · App. 12/529,001 · Granted May 17, 2011

Activated polyoxazolines and compositions comprising the same

Assignee: Serina Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,141
App. No.
12/529,001
Granted
May 17, 2011
Kind
B2
Abstract

The present disclosure provides terminally activated monofunctional POZ derivatives having a range of functional active groups allowing conjugation of the monofunctional POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed terminally activated monofunctional POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives.

Claims (38)

1. A terminally activated polyoxazoline compound having the general structure R 1 —[N(COR 7 )CH 2 CH 2 ] n —S-Q q -X,

wherein

X is an active functional group capable of forming a hydrolytically stable linkage with a target molecule to form a target molecule-POZ conjugate wherein all the linkages between the target molecule and the POZ compound are hydrolytically stable in a biological system;

Q is an optional linking group;

R 1 , and is hydrogen or an unsubstituted or substituted alkyl, alkenyl or aralkyl group;

R 7 is independently selected for each repeating unit from an unsubstituted or substituted alkyl, alkenyl or aralkyl group;

n is an integer from 3 to 1000; and

q is zero or one.

2. The compound of claim 1 where the active functional group is protected.

3. The compound of claim 1 where R 7 has from 1 to 12 carbon atoms.

4. The compound of claim 1 where R 7 is methyl, ethyl or n-propyl.

5. The compounds of claim 1 where the active functional group is selected from the group consisting of aldehydes, active carbonates (—O—CO—Z), maleimides, sulfonate esters (OSO 2 —R 23 ), hydrazide, epoxides, iodoacetamides, alkynes, azides, isocyanates, cyanates isothiocyanates, thiocyanates, nitriles, carbonyldiimidazole derivatives, vinylsulfones, carboxylic acid halides, active esters (—CO—Z) and carboxylic acids, wherein any of the foregoing may be substituted or unsubstituted, Z is an activating group and R 23 is an unsubstituted or substituted alkyl, alkenyl, alkynyl, aralkyl or aryl group.

6. A target molecule POZ conjugate of the general formula A-B-TM, wherein

A is a terminated POZ compound of claim 1 , minus any leaving groups eliminated during the reaction of the active functional group on the POZ compound with a binding partner on a target molecule;

TM is the target molecule, said target molecule containing the binding partner; and

B is a linkage that is hydrolytically stable in a biological system that is formed between the active functional group and the binding partner.

7. The conjugate of claim 6 wherein the active functional group is a maleimide, the binding partner is SH and B is a thioether linkage.

8. The conjugate of claim 6 wherein the active functional group is an active carbonate, the binding partner is NH 2 and B is a urethane linkage.

9. The conjugate of claim 6 wherein the active functional group is an active ester, the binding partner is NH 2 and B is an amide linkage.

10. The conjugate of claim 6 wherein the active functional group is an aldehyde, the binding partner is NH 2 and B is an amine linkage.

11. A method of synthesizing terminally activated polyoxazoline (POZ) compound, said method comprising the steps of:

(a) initiating POZ polymerization to form a POZ polymer with a positive cation on the terminating end; and

(b) terminating said POZ polymer with a mercaptide.

12. The method of claim 11 where the mercaptides comprises the structure R 25 S-D d -X wherein

X is an active functional group or a group capable of being converted to an active functional group, the active functional group capable of forming a hydrolytically stable linkage with a target molecule to form a target molecule-POZ conjugate;

R 25 is a metal;

D is a linking group; and

d is 0 or 1.

13. The method of claim 12 where R 25 is Li, Na or K.

14. The terminally activated polyoxazoline compound of claim 1 having the structure:

(b) CH 3 —[N(COCH 2 CH 3 )CH 2 CH 2 ] n —S—CH 2 CH 2 —CO 2 H

(c) CH 3 —[N(COCH 2 CH 3 )CH 2 CH 2 ] n —S—CH 2 —CO 2 H

(d) CH 3 —[N(COCH 2 CH 3 )CH 2 CH 2 ] n S—CH 2 CH 2 —NH 2

(f) CH 3 —[N(COCH 2 CH 2 CH 3 )CH 2 CH 2 ] n —S—CH 2 CH 2 —CO 2 H

(g) H—[N(COCH 2 CH 3 )CH 2 CH 2 ] n —S—CH 2 CH 2 —CO 2 H

15. The compound of claim 1 , wherein the linking group Q is an unsubstituted or substituted alkyl, alkenyl, aralkyl, heterocyclyl or aryl group, —(CH 2 ) m —CONH—(CH 2 ) m —, —NH—(CH 2 ) m —NHCO—(CH 2 ) m —, —CO—(CH 2 ) m —, —CO—C 6 H 4 —, or —CO—R 8 , —(R 15 ) m — or —(CR 3 R 4 ) m —, wherein m is independently an integer from 1 to 10, R 3 , R 4 , R 11 and R 15 are each independently selected from hydrogen or an unsubstituted or substituted alkyl, alkenyl or aralkyl group and R 8 is —C 6 H 10 —CH 2 —.

16. The compound of claim 1 wherein the POZ polymer has a polydispersity value of less than or equal to 1.20.

17. The method of claim 12 wherein the linking group D is an unsubstituted or substituted alkyl, alkenyl, heterocyclyl or aryl group.

Assignments (2)
CHANGE OF NAME Recorded Apr 8, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067036/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2010
From: BENTLEY, MICHAEL DAVID; HARRIS, J. MILTON; YOON, KUNSANG; FANG, ZHIHAO; VERONESE, FRANCESCO MARIA
To: SERINA THERAPEUTICS, INC.
Reel/Frame 023842/0453 →
Continuity (2)
Provisional Application 60892212 · Feb 28, 2007
Related Publication 20100069579A1 · Mar 18, 2010